The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Infanrix hexa



GlaxoSmithKline Biologicals S.A.EU/1/00/152/19-20

Main Information

Trade NameInfanrix hexa
Active SubstancesTetanus toxoid
Conjugate of haemophilus influenzae type b capsular polysaccharide (prp) and tetanus toxoid
Pertactin (69 kda outer membrane protein - prn)
Diphtheria toxoid (d)
Inactivated polio virus type 2
R-dna hepatitis b surface antigen (hbsag)
Inactivated polio virus type 1
Pertussis toxoid
Inactivated polio virus type 3
Filamentous haemagglutinin
Dosage FormPowder and suspension for suspension for injection
Licence HolderGlaxoSmithKline Biologicals S.A.
Licence NumberEU/1/00/152/19-20

Group Information

ATC CodeJ07CA Bacterial and viral vaccines, combined
J07CA09 diphtheria-hemophilus influenzae B-pertussis-poliomyelitis-tetanus-hepatitis B

Status

License statusAuthorised
Licence Issued
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusUnknown

Documents

Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website
« Back